
    
      This is a Phase 1, dose-escalation study in female patients with recurrent or persistent
      gynecologic tumors. The study will include a Screening Phase, a Treatment Phase and a
      Followup Phase. In the Screening Phase the subject's eligibility for study participation will
      be determined; this phase can last up to 28 days. The Treatment Phase will begin when the
      subject starts study treatment and will continue until the subject is removed from study
      treatment. The Follow-up Phase will last for 30 days after the subject ends study treatment.
      The study will be conducted at approximately 1 site. Treatment cycle length is 28 days.
      Radiologic imaging will be repeated after every 2 cycles of treatment.
    
  